Navigation Links
Micromet Key Events for 2009
Date:1/5/2009

ested to date have been hampered by cancer cells' ability to escape recognition by T cells. The use of BiTE antibodies that are specifically designed to engage T cells for attacking cancer cells may provide a more effective anti-tumor approach than conventional monoclonal antibodies.

About Micromet, Inc.

Micromet, Inc. (www.micromet-inc.com) is a biopharmaceutical company with offices in Bethesda, Maryland and Munich, Germany. The Company is developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases. The Company uses its proprietary BiTE(R) antibody platform to create a new class of antibodies that specifically activate T cells from the patient's own immune system to eliminate cancer cells or other disease-related cells. Four of the Company's antibodies are currently in clinical trials, with the remainder of its product pipeline in preclinical development. The Company's lead program is a BiTE antibody known as blinatumomab, or MT103. It is in a phase 2 clinical trial for the treatment of patients with acute lymphoblastic leukemia and a phase 1 clinical trial for the treatment of patients with non-Hodgkin's lymphoma. Micromet is developing blinatumomab in collaboration with MedImmune, a subsidiary of AstraZeneca plc. Micromet's second BiTE antibody in clinical development is MT110, which targets the epithelial cell adhesion molecule (EpCAM). The Company owns all rights to MT 110, which is currently in a phase 1 clinical trial for the treatment of patients with solid tumors. The Company's third clinical stage antibody is adecatumumab, also known as MT201, a conventional human monoclonal antibody that targets EpCAM-expressing solid tumors. Micromet is developing adecatumumab in collaboration with Merck Serono in a phase 1b clinical trial evaluating adecatumumab in combination with docetaxel for the treatment of pa
'/>"/>

SOURCE Micromet, Inc.
Copyright©2009 PR Newswire.
All rights reserved

2

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Micromet Expands Committed Equity Financing Facility to $75 Million
2. Micromet Presents Data at the 23rd Annual Meeting of the International Society for Biological Therapy of Cancer on the Activity of Human Antibody Adecatumumab against KRAS-mutated Colon Cancer Cells
3. Micromet Presents Data at ESMO 2008 on Anti-EpCAM Antibody Adecatumumab (MT201) in Combination with Chemotherapy
4. Micromet, Inc. to Host Webcast and Conference Call to Discuss Blinatumomab Data Published in SCIENCE
5. Micromet, Inc. to Host Conference Call and Webcast to Discuss Second Quarter 2008 Financial Results
6. Micromet and Nycomed Begin Formal Preclinical Safety Studies for Antibody MT203 for Inflammatory and Autoimmune Diseases
7. Micromet and MedImmune Commence Treatment in Phase 2 Trial of BiTE Antibody Blinatumomab (MT103/MEDI-538) in Patients with Acute Lymphoblastic Leukemia
8. Micromets BiTE Antibody Blinatumomab (MT103/MEDI-538) Demonstrates Durable Responses in Patients with Relapsed Non-Hodgkins Lymphoma
9. Micromet to Present Clinical Update for BiTE Antibody MT103/MEDI-538 at the International Conference on Malignant Lymphomas
10. Micromet Enrolls First Patient in a Phase 1 Clinical Trial with MT110, the First BiTE Antibody for Treatment of Solid Tumors
11. Micromet Shows Feasibility of Subcutaneous Delivery of BiTE Antibody in Preclinical Primate Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/20/2013)... Ill. , May 20, 2013 Landauer, ... in personal and environmental radiation measurement and monitoring, outsourced ... announced today that its Board of Directors declared, at ... cash dividend of $0.55 per share for the third ... on July 3, 2013, to shareholders of record on ...
(Date:5/20/2013)... May 20, 2013  Valeant Pharmaceuticals International, Inc. (NYSE: ... senior management team will make a presentation at the 34 ... 11, 2013 at 9:20 a.m. PT. The conference will be ... CA. A live webcast and audio ... Web site at www.valeant.com . Click on Investor Relations, ...
(Date:5/20/2013)... VIEW, Calif. , May 20, 2013 /PRNewswire-iReach/ ... results of the first study demonstrating detection of ... Yersinia pestis and Bacillus anthracis ... Control and Prevention,s list of potential bio-threats. This ... Science and Technology Laboratory, Salisbury ...
Breaking Medicine Technology:Landauer, Inc. Declares Regular Cash Dividend 2Specific Technologies Detects and Identifies Potential Bioterrorism Pathogenic Bacteria 2
... April 18, 2011 Altitude Organic Corporation (Pinksheets: ... announced today that it has launched its third-party ... headquarters.  Visit the DoctorMMJ.com website ( www.DoctorMMJ.com ) ... and entirely legal medical marijuana evaluation in Arizona. ...
... 2011 Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN ... Administration (FDA) has accepted for review the Company,s Biologics ... of the neovascular form of age-related macular degeneration (wet ... priority review of its BLA.  A Priority Review designation ...
Cached Medicine Technology:Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 2Altitude Organic Corporation Opens DoctorMMJ.com Physician Referral Service in Scottsdale, Arizona 3FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 2FDA Grants Priority Review for VEGF Trap-Eye for the Treatment of Wet Age-Related Macular Degeneration 3
(Date:5/21/2013)... 21, 2013 The birth control safety ... who have used the contraceptive NuvaRing. A new report ... clot injuries has increased in recent months*. , DrugRisk ... and devices with the latest safety alerts, recalls, studies ... are experiencing similar side effects and decide if they ...
(Date:5/20/2013)... 2013 USA Book News announced Monday ... Peak Performance" won the top honor in its 2013 ... over a multitude of international titles published from 2011-2013, ... acclaim from both mainstream and new age audiences looking ... and spiritually. , “The Infinity Zone” is ...
(Date:5/20/2013)... Texas (PRWEB) May 21, 2013 ... on product type into two categories - semi-automated ... market is classified into five categories, namely, hospitals, ... market is forecast till 2017. Automated external defibrillators ... of sudden cardiac arrest victims. Considering the life-saving ...
(Date:5/20/2013)... (PRWEB) May 20, 2013 Recent ... importance of using green and sustainable inputs in ... has implemented regulations to promote the use of ... Packaging and Labelling Services industry . “Tax subsidies ... trend,” says IBISWorld industry analyst Deonta Smith. “For ...
(Date:5/20/2013)... Florida (PRWEB) May 20, 2013 In order ... supplemental health and wellness team from DrSmartphoneMD launched an article ... serious sunburns. , The series launched with the ... that members of the DrSmartphoneMD program are not one of ... team explained that more than 90% of all skin cancer ...
Breaking Medicine News(10 mins):Health News:DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 2Health News:Mystic Ink Publishing's "The Infinity Zone" Wins Top Honor - International Book Awards 3Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 2Health News:North America Leads Automated External Defibrillator Market (AED), Says New Research Report at ReportsnReports.com 3Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 2Health News:Packaging and Labelling Services in Canada Industry Market Research Report Now Available from IBISWorld 3Health News:Combat Skin Cancer In Summer Months 2
... study shows that combining high resolution and high sensitivity ... emission computed tomography (SPECT) scans, said researchers at SNM,s ... rays so that only those traveling parallel to a ... it is not yet possible to focus radiation with ...
... skin patch can safely and successfully treat basal cell ... cancers, according to researchers at the SNM,s 56th Annual ... is nontoxic and could be an excellent alternative to ... treatments is difficult. "While basal cell carcinoma is ...
... pandemic level, a new article http://www.cmaj.ca/cgi/rapidpdf/cmaj.090866 in ... oseltamivir (Tamiflu) and zanamivir (Relenza) are relatively safe drugs ... women, especially those in the third trimester, are at ... influenza virus. The study was conducted by researchers ...
... , Brand unveils four-month awareness campaign featuring Len Dawson, Ken Griffey ... with ZERO - The Project to End Prostate Cancer , ... staggering one in six men and 192,000 men expected to be ... KMB ) and the Depend brand today announced a ...
... Insight built on SAP(R) BusinessObjects(TM) software , ... /PRNewswire/ -- Tata Consultancy Services (TCS) ... business solutions and outsourcing firm, has launched Provider ... on SAP(R) BusinessObjects(TM) software for hospitals and other ...
... stories and demands for solutions to lawmakers in Washington , ... , ATLANTA, June 15 As lawmakers wrangle over health reform ... one mom is making sure people,s voices are heard. Kathie McClure, ... states to expose the gaps in our tattered healthcare system safety ...
Cached Medicine News:Health News:New skin cancer patch: Possible alternative to surgery 2Health News:Kimberly-Clark Teams Up With Sports Legends to Launch 'The Depend Campaign to End Prostate Cancer' 2Health News:Kimberly-Clark Teams Up With Sports Legends to Launch 'The Depend Campaign to End Prostate Cancer' 3Health News:Kimberly-Clark Teams Up With Sports Legends to Launch 'The Depend Campaign to End Prostate Cancer' 4Health News:Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 2Health News:Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 3Health News:Tata Consultancy Services Launches New Business Intelligence Solution for Hospitals and Healthcare Providers 4Health News:Mom on Mission for Quality, Affordable Healthcare for All Drives Purple Bus Across Nation Gathering Stories 2Health News:Mom on Mission for Quality, Affordable Healthcare for All Drives Purple Bus Across Nation Gathering Stories 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: